Platinum-Resistant Fallopian Tube Carcinoma
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenentechVismodegib
IpsenBevacizumab
PrecigenPRGN-3005 UltraCAR-T cells
Clinical Trials (3)
Total enrollment: 122 patients across 3 trials
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Start: May 2023Est. completion: Mar 203348 patients
Phase 2Recruiting
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Start: Mar 2021Est. completion: Oct 20213 patients
Phase 2Completed
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Start: Apr 2019Est. completion: Nov 202871 patients
Phase 1Active Not Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3h ago
Office Administrator
SystImmune
3h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 122 patients
3 companies competing in this space